The optimal approach to treat invasive fungal disease (IFD) caused by more than one fungal species is unknown. We documented the efficacy and safety of isavuconazole for Fifteen patients were included in this analysis (including Aspergillus spp., n = 11; without Aspergillus spp., n = 4); median treatment duration was 97 days [range, 6-544] days).
| INTRODUC TI ON
Invasive fungal diseases (IFDs) are responsible for considerable morbidity and mortality, especially in immunocompromised individuals, including those with haematological malignancies or recipients of solid organ or haematopoietic-cell transplantations. 1 Antifungal treatment options for most IFDs include amphotericin B formulations, echinocandins, and triazole antifungal agents, although each may be associated with limitations that include pathogen susceptibility and patient tolerability. 2 Despite that IFDs in clinical practice usually involve a single fungal pathogen, concurrent infections with more than one fungal species have been reported in case studies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and retrospective analyses. [18] [19] [20] A multiple-species IFD may pose a unique clinical challenge because of the potential for increased virulence and different susceptibility profiles of the pathogens.
Isavuconazole is the active moiety of the prodrug isavuconazonium sulphate, a triazole antifungal agent active against a variety of fungal pathogens in vitro and in vivo and available in oral and intravenous formulations. 21 Isavuconazole was demonstrated to be non-inferior to voriconazole for the treatment of invasive aspergillosis in adults in the Phase III SECURE trial and was associated with fewer drug-related treatment-emergent adverse events (TEAEs). 22 The efficacy of isavuconazole treatment in adults with mucormycosis was also similar to that of amphotericin B in casematched controls in the Phase III VITAL trial. 23 As a result, the US One objective of the VITAL trial was to test the efficacy and safety of isavuconazole for treatment of emerging IFD caused by fungal species other than Aspergillus fumigatus or Candida species. In addition to mucormycosis, isavuconazole demonstrated activity against Cryptococcus and dimorphic fungi 24 as well as other rare or non-speciated fungal pathogens (see accompanying article 25 ). In this article, we present the results of the VITAL trial in patients with documented IFD caused by more than one fungal species.
| ME THODS

| Trial design
The VITAL trial was a Phase III, international, single-arm, multicentre, open-label study to evaluate the efficacy and safety of isavuconazole in the treatment of invasive aspergillosis in patients with renal impairment and of rare fungal infections (ClinicalTrials.gov identifier: NCT00634049). Additional details regarding methods are presented in an accompanying article 26 and details of methods and other results from VITAL have been reported elsewhere. [23] [24] [25] The subset of patients with IFD caused by multiple fungal species is presented here. The study was conducted in accordance with the Declaration of Helsinki (2000) and the International Conference on Harmonisation Guidelines for Good Clinical Practice. The study was approved by the institutional review board at each study centre and all patients provided written informed consent prior to enrolment.
| Patients and treatment
Patients enrolled in the VITAL trial were aged ≥18 years with body weight ≥40 kg, with a rate-corrected QTc interval of <500 ms, and no concurrent treatment with strong inhibitors or inducers of cytochrome P450. 
| Assessments
The primary endpoint was the overall response to treatment at Day methodologies. [28] [29] [30] [31] Baseline characteristics, efficacy outcomes and TEAEs with an onset within 28 days of the last dose of isavuconazole were summarised using descriptive statistics. 
| RE SULTS
| Efficacy
Overall treatment success was observed in 2/15 patients (13.3%)
at Days 42 and 84, and 2/14 patients (14.3%) at EOT. One patient continued treatment beyond the end of the study and therefore no EOT assessment was performed ( Table 3 .
| In vitro susceptibility
Susceptibility testing results (CLSI and EUCAST MICs) were available from 14 pathogens isolated from ten patients, including one patient who was a treatment success (Patient 13) ( Not assessed 
| Safety
All patients experienced at least one TEAE ( Table 5 ). The most common TEAEs were headache, herpes zoster, hypoalbuminaemia, and pyrexia. In the group of patients with Aspergillus spp. 
| D ISCUSS I ON
In this group of 15 patients from VITAL with IFDs caused by more than one fungal species, confirmed survival throughout the entire study was 60% (9/15), with two patients deemed to be an overall treatment success at EOT. Since IFDs involving more than one pathogen are likely to increase with a growing population of immunocompromised patients, this report highlights key issues that are necessary to provide context for therapeutic outcomes.
The probability of IFD caused by multiple fungal species may be higher in patients whose defences are more profoundly compromised, 32 and the underlying diseases and their management are With Aspergillus (n = 11) Without Aspergillus (n = 4) TA B L E 3 (Continued) more complex. Therefore, it might reasonably be expected that this would be reflected in worse treatment outcomes in patients with IFD caused by multiple fungal species. Consistent with this expectation, fatal outcomes were reported in more than half of the case reports we found in a search of the literature for patients with IFD involving multiple fungal species. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] This figure may be underesti- Given the established activity of isavuconazole for mucormycosis and aspergillosis, 22, 23 these data may be helpful to supplement other information regarding activity against some of the other rare co-infecting pathogens. 25 For example, even in the absence of complete treatment success, the survival of Patient 2 (aspergillosis and fusariosis) could be supportive of other evidence for the potential activity of isavuconazole in patients with fusariosis only. 25, 33 In fact, it
is not clear whether the lack of treatment success in that patient was representative of some degree of drug-resistance of that pathogen or development of cross-resistance in one or both pathogens due to the prior unsuccessful treatment of the patient with voriconazole. Lomentospora (Scedosporium) prolificans due to the limited in vitro susceptibility of that pathogen (MIC >16 μg/ml).
The susceptibilities of pathogens from patients in this study to isavuconazole were within the ranges of MICs observed in previous studies. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] The results for two isolates deserve mention. An MIC value >16 μg/ml was observed for an isolate of A. flavus from Patient 3 (see Results). This result could have been spurious, or may represent a case of azole resistance, which has recently been described in A. flavus isolates. 45, 46 The R. arrhizus isolate from Patient 10 was found to have an MIC for isavuconazole of >16 μg/ml using both methods, which may represent an R. arrhizus var. delemar variant. 44 It is also notable that four of the five patients who died during the study had isolates with high isavuconazole MIC values of ≥8 μg/ml 
